S&P Futures
4,341.75 +16.25 (+0.38%) Dow Futures
33,853.00 +128.00 (+0.38%) Nasdaq Futures
14,945.75 +79.25 (+0.53%) Russell 2000 Futures
1,806.20 +7.60 (+0.42%) Crude Oil
91.14 +0.35 (+0.39%) Gold
1,862.70 -3.40 (-0.18%)
Benitec Biopharma Inc. (BNTC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.0000 |
| Open | 3.0700 |
| Bid | 3.0000 x 1100 |
| Ask | 3.2300 x 800 |
| Day's Range | 3.0100 - 3.1000 |
| 52 Week Range | 1.8600 - 9.0100 |
| Volume | |
| Avg. Volume | 607,167 |
| Market Cap | 7.693M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -236.2600 |
| Earnings Date | Nov 08, 2023 - Nov 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BNTC
Related Research
- Benitec Biopharma Inc.Analyst Report: Viatris Inc.Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.RatingFair ValueEconomic Moat2 months agoMorningstar
GlobeNewswireBenitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment Study Successful Closing of a $30.9 M Public Offering HAYWARD, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or
GuruFocus.comCitadel Advisors LLC Acquires New Stake in Benitec Biopharma Inc
On August 11, 2023, Citadel Advisors LLC, a renowned investment firm, made a significant move in the stock market by acquiring a new stake in Benitec Biopharma Inc. This article provides an in-depth analysis of this transaction, the profiles of both Citadel Advisors LLC and Benitec Biopharma Inc, and the potential implications for value investors. Citadel Advisors LLC purchased 173,880 shares of Benitec Biopharma Inc at a price of $2.81 per share. This transaction marked a new holding for the firm, increasing their total shares in Benitec Biopharma Inc to 173,880.
GuruFocus.comJANUS HENDERSON GROUP PLC Acquires New Stake in Benitec Biopharma Inc
On August 9, 2023, JANUS HENDERSON GROUP PLC, a London-based investment firm, made a significant move in the biotechnology sector by acquiring 206,170 shares of Benitec Biopharma Inc (NASDAQ:BNTC). Despite the substantial share acquisition, the impact on the firm's portfolio was not significant, with the position in BNTC representing 0% of the total portfolio. The firm now holds 9.90% of Benitec Biopharma Inc's total shares.
